As new medications enter the market, we’ve observed a troubling new trend: an influx of clinically superfluous brand drugs that carry hefty price tags but offer little to no added clinical value.
Recently, manufacturers have launched new brand-name prescription wound dressings that include similar combinations of ingredients as OTC and lower-cost generic products yet are priced far higher than the alternatives — up to 125 times more.
This report shines a spotlight on:
- What’s driving the increased need for wound care.
- The potential effects of high-cost prescription wound dressings on patients and plan sponsors.
- How Optum Rx helps improve the quality of care while lowering costs.
Related healthcare insights
Article
Explore how real-time connections can enable more accurate claim submission to create a more efficient healthcare payment system.
Article
Learn strategies for managing members at risk of medication nonadherence, from initiation to renewal.
Article
Hundreds of clinical trials are vetting GLP-1s to treat everything from Alzheimer’s to arthritis. The question is: How will we afford it?